Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) Starts Presentation at 29th Annual ROTH Conference
Foamix Pharmaceuticals (NASDAQ: FOMX) is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. The company’s clinical stage product candidates include FMX101, a novel minocycline foam for the treatment of moderate-to-severe acne; FMX103 for the treatment of moderate-to-severe rosacea; FMX102 for the treatment of impetigo; and FDX104, a doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs. In addition, Foamix has development and license agreements relating to its technology with various pharmaceutical companies including Bayer HealthCare and others. For more information, visit the company’s website…







